Professional Documents
Culture Documents
Rancangan New Dosage Form
Rancangan New Dosage Form
3. Stabilitas
Stabilitas fisikokimia sampel dievaluasi selama 6 bulan dengan suhu dan kelembaban
25±2˚ C % 60 ± 5.
Valsartan (50%)
Formula MCC PH 200(18%)
(berat 160 HPMC K100(16,5%)
mg/tab) Natrium sitrat(15%)
Magnesium stearate(0,5%)
Preformulasi
Valsartan Valsartan memiliki ketersediaan hayati yang rendah (AUC 23%)
karena terkait dengan kelarutannya yang buruk dalam air pada pH
rendah (1,2) yaitu 87 μg / ml tetapi meningkat menjadi 5 mg / ml
pada pH 6.8 (Park et al, 2018)
HPMC K100
Natrium sitrat
Depkes RI. Farmakope Indonesia Edisi VI. 2020 Kementerian Kesehatan Republik Indonesia.
Ahad, A., Aqil, M., Kohli, K., Sultana, Y., & Mujeeb, M. 2014. Design, formulation and
optimization of valsartan transdermal gel containing iso-eucalyptol as novel
permeation enhancer: Preclinical assessment of pharmacokinetics in Wistar albino
rats. Expert Opinion on Drug Delivery, 11(8), 1149–1162.
https://doi.org/10.1517/17425247.2014.914027
Dashevsky A, Kolter K, Bodmeier R. pH-independent release of a basic drug from pellets coated
with the extended release polymer dispersion Kollicoat SR 30 D and the enteric polymer
dispersion Kollicoat MAE 30 DP. Eur J Pharm Biopharm. 2004;58:45–49.
Park, J. B., Park, C., Piao, Z. Z., Amin, H. H., Meghani, N. M., Tran, P. H. L., Tran, T. T. D.,
Cui, J. H., Cao, Q. R., Oh, E., & Lee, B. J. 2018. pH-independent controlled release
tablets containing nanonizing valsartan solid dispersions for less variable
bioavailability in humans. Journal of Drug Delivery Science and Technology, 46,
365–377. https://doi.org/10.1016/j.jddst.2018.05.031
Pharmacopeia United States. USP General Chapter h711i Dissolution. Rockville (MD): US
Pharmacopeial Conv. United B. Press; 2011. p. 1–8.
Abbaspour, M., Iraji, P., Mahmoudi, Z., Rahiman, N., & Akhgari, A. 2021. Design and physico-
mechanical evaluation of fast-dissolving valsartan polymeric drug delivery system by
electrospinning method. Iranian Journal of Basic Medical Sciences, 24(12), 1683–
1694. https://doi.org/10.22038/IJBMS.2021.58713.13041
Flesch G, Muller PH, Lloyd P. 1997. Absolute bioavailability and pharmacokinetics of valsartan,
an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 52:115–20.
Kumar, A., Davern, P., Hodnett, B.K., Hudson, S.P., 2019. Carrier particle mediated stabilization
and isolation of valsartan nanoparticles. Colloids Surfaces B Biointerfaces175,554–
563.https://doi.org/10.1016/j.colsurfb.2018.12.021
Trunov, D., Francisco Wilson, J., Jeˇzkov´ a, M., Srom, ˇ O., Beranek, J., Dammer, O., Soˇ o´ˇs,
M., 2021. Monitoring of particle sizes distribution during Valsartan precipitation in
the presence of nonionic surfactant. Int. J. Pharm. 600 https://doi.
org/10.1016/j.ijpharm.2021.120515.
Vidyadharma S. 2004. formulation-and-evaluation-of-propranolol-hydrochloride-oral-controlled-
release-matrix-tablets. Indian J.Pharm. Sci, 2(66), 188–192.